Neuroscience R&D Technologies Conference

Transcription

1 4 th Annual Event Overview Neuroscience research continues to evolve in order to cope up with changing industry dynamics. Recent strategic partnerships and mergers have not only experienced R&D cuts but also shut down of entire R&D sites. As a result, industry is now more keen on investing in biotechnology start-ups to build their new pipeline for neuro products. Discovering medicines to treat neurodegenerative disorders like Alzheimer s, Parkinson s and Dementia has been extremely challenging in the past decades. But through recent advances in stem cell technology, functional neuroimaging, better animal models, neuromodulation and deep brain stimulation; scientific understanding and expectations are now gathering pace. The 4th Annual being held on 4th - 5thOctober in Munich, Germany will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims bringing in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries. There would be live case studies, keynote presentations and breakthrough panel discussion sessions during the two-day meet. Key Highlights: Human IPSC and Blood Brain Barrier Pre-clinical/Translational developments in CNS Functional Neuroimaging Technologies Optogenetics in brain mapping Animal Models and mechanisms Disease modeling and drug discovery Deep brain stimulation and neuromodulation Why attend? First ever conference on application of technology in developing neurological treatments Meet global heads of neuroscience from the industry and Academics 100+ neuroscience professionals attending Access to online presentations on-demand post-summit Case studies presented from leading technology collaborations Interactive panel and breakout sessions Who should attend? From Pharmaceutical, Academics and Research Institutes - Chief Scientific Officer/Directors/Heads/VP/Managers/Senior Scientists/ Principal/ Scientist/ Neuroscientists/Project Leaders/Professors/Research Fellows in: Neuroscience/CNS drug discovery Translational Neuroscience Pre-clinical research Computational Neuroscience/Neuroinformatics Neurotechnology Neuroimaging/Translational Imaging Neurodegenerative diseases Neuroengineering Neuropharmacology/Neurobiology Neuromorphic engineers

2 4th Annual Scientific Advisory Panel Georg Terstappen, Head, Platform Technologies & Science China and PTS Neurosciences TA Portfolio Leader, GSK, China Thomas Jahn, Lab Head and Project Lead, Neuroscience Discovery, AbbVie, Germany Dirk Schubert, Assistant Professor, Cellular Neurophysiology, Radboud University, Netherlands Georg Terstappen, Head, Platform Technologies & Science China and PTS Neurosciences TA Portfolio Leader, GSK, China Thomas Jahn, Lab Head and Project Lead, Neuroscience Discovery, AbbVie, Germany Dirk Schubert, Assistant Professor, Cellular Neurophysiology, Radboud University, Netherlands Simon Schultz, Director, Neurotechnology, Imperial College London, UK Yang (Ted) Teng, Co-Director, Neurotrauma Recovery Research, Harvard Medical School, USA Peter St. George-Hyslop, Director, Neurodegenerative Research, University of Toronto, Canada Robert Joe Mather, Executive Director, Head of Digital Collaborations, Pfizer, USA Emilio Merlo-Pich, Vice President, Takeda, UK Richard Wade-Martins, Professor, Molecular Neuroscience, Oxford University, UK Nael Nadif Kasri, Group Leader, Molecular Neurophysiology, Radboud University, Netherlands Fiona Elwood, Head, Neurodegeneration, Novartis, USA York Winter, Professor, Cognitive Neurobiology, Charite University, Germany James Ellis, Research Integrity Advisor, The Hospital for Sick Children, USA Jean-Pierre Mothet, Director, Research CNRS, AixMarseille University, France Gordon Pipa, Chair, Neuroinformatics, University of Osnabrueck, Germany John Isaac, Senior Director, Neuroscience External Innovation, Johnson & Johnson London Innovation Centre, UK Michael Coleman, Professor, Neuroscience, University of Cambridge, UK Jonathan Van Eyll, Senior Principal Scientist, Bioinformatics, UCB, Belgium Expert Speaker Panel Marianna Semprini, Post Doc, Italian Institute of Technology, Italy

3 08:15 Registration Day 1, 4 th October :55 Welcome note from MarketsandMarkets Human ipsc and Blood Brain Barrier 09:00 Opening Remarks from the Chairman 09:10 Keynote Presentation - Experimentally Modeling Spinal Cord Glioblastoma for Oncolytic Targets Identification by Genetically Engineered hnscs We have established a rodent model of intramedullary spinal cord glioblastoma (ISCG) that for the first time emulated both somatomotosensory and autonomic dysfunctions of this deadly disease. Using genetically engineered human neural stem cells (hnscs) that track cancer cells we determined a subpopulation of ISCG cells that are crucial for tumor survival and can be targeted by therapeutic hnscs that exert localized oncolytic effect. Our findings demonstrate a stem cell-based multimodal approach to developing targeted glioblastoma treatments following Recovery Neurobiology principles. Yang (Ted) Teng, Co-Director, Neurotrauma Recovery Research, Harvard Medical School, USA 9:40 Brain delivery technologies for CNS therapeutics Development of therapeutics for diseases of the central nervous system is compromised by the presence of the blood-brain barrier Therefore, there is an urgent need for efficient brain delivery technologies in order to enable the development of CNS therapeutics, especially biopharmaceuticals In recent years a significant number of diverse technologies have been developed and tested in laboratory and clinical studies but none of these is turn-key yet. Georg Terstappen, Head, Platform Technologies & Science China and PTS Neurosciences TA Portfolio Leader, GSK, China 10:10 Solution Provider Presentation; 10:25 Morning Refreshments and Poster Presentation One-to-One Networking Meetings 11:10 Target and drug discovery in Parkinson s stem cell-derived neurons Parkinson s induced pluripotent stem cell (ipsc)-derived dopamine neurons provide mechanistic insight into disease processes Single cell transcriptomics of Parkinson s ipsc-derived dopamine neurons reveals novel drug targets Phenotypic screening in Parkinson s ipsc-derived dopamine neurons identifies new candidate drugs Richard Wade-Martins, Professor, Molecular Neuroscience, Oxford University, UK 11:40 Penetrating the BBB using NeuroCART 12:10 Solution Provider Presentation; 12:40 Brain-on-chip-technology for modeling neurodevelopmental disorders ipsc-derived neurons on multi-electrode arrays as a tool to understand genetic-phenotype relationship ipsc-derived neurons on multi-electrode arrays for targeted semi-high throughput drug studies Nael Nadif Kasri, Group Leader, Molecular Neurophysiology, Radboud University, Netherlands 13:10 Lunch and Poster Presentation One-to-One Networking Meetings

4 Preclinical/Translational Developments in CNS Functional Neuroimaging Technologies 14:10 Applying novel technologies to advance Tau drug discovery for neurodegeneration CRISPR screens to identify Tau modulators Models of Tau aggregation using ipsc derived neurons Microdialysis to resolve extracellular Tau species in vivo Fiona Elwood, Head, Neurodegeneration, Novartis, USA 14:10 EEG as a biomarker in identifying neurodegenerative diseases 14:40 Solution Provider Presentation; 14:40 Solution Provider Presentation; 14:55 ips cell models of neurodevelopmental disorders Patient ips cell models of Autism Spectrum Disorder CRISPR knockout of ASD candidate genes Functional phenotyping using multielectrode arrays James Ellis, Research Integrity Advisor, The Hospital for Sick Children, USA 15:25 Axon and synapse degeneration Wallerian degeneration after axon injury Wallerian-like degeneration in uninjured axons Organotypic slice culture models of Alzheimer s disease Michael Coleman, Professor, Neuroscience, University of Cambridge, UK 14:55 Optogenetic tools for controlling neuronal circuits used in brain mapping 15:25 Solution Provider Presentation; 15:40 Afternoon Refreshments and Poster Presentation One-to-One Networking Meetings 16:25 Human induced pluripotent stem cells (ipscs) derived neuronal networks allow phenotyping neurodevelopment disorders on the chip Controlled differentiation of induced pluripotent stem cells into specific types of neurons allow assessing cell type specific contribution to disease phenotypes. From gene to network function approach: in depth analyses of molecular, morphological and functional parameters offer a platform for identifying disease specific biomarkers. Dirk Schubert, Assistant Professor, Cellular Neurophysiology, Radboud University, Netherlands 16:25 Functional connectivity using FMRI, PET and EMG for Neurodegenerative diseases 16:55 Patient centric drug design and testing 16:55 Non-invasive methodologies of brain stimulation to develop an algorithm using EEG/EMG 17:25 Closing Remarks from the Chairman 17:25 Closing Remarks from the Chairman 17:30 Drinks Reception & Networking End of Day 1

5 08:15 Registration Day 2, 5 th October :55 Welcome note from MarketsandMarkets Animal Models and Mechanisms 09:00 Opening Remarks from the Chairman 09:10 Keynote Presentation 9:40 Challenges and innovations in drug discovery for neurodegenerative disorders new technologies innovation in collaboration across sectors John Isaac, Senior Director, Neuroscience External Innovation, Johnson & Johnson London Innovation Centre, UK 10:10 Solution Provider Presentation; 10:25 Morning Refreshments and Poster Presentation One-to-One Networking Meetings 11:10 Benefits and Limitations of Animal models for translational research 11:40 Challenges in using transgenic rodents for Alzheimer s disease 12:10 Solution Provider Presentation; 12:40 Panel: Challenges in translation from preclinical to clinical research in CNS drug discovery 13:10 Lunch and Poster Presentation One-to-One Networking Meetings Disease Modeling and Drug Discovery 14:10 Modeling human brain development using human ipsc derived organoids 14:40 Molecular and translational modeling of diseases, experimental models & treatments : a transcriptomics-based approach Deep Brain Stimulation and Neuromodulation 14:10 Neuromodulation for Neurodegenerative disorders 14:40 Solution Provider Presentation; Jonathan Van Eyll, Senior Principal Scientist, Bioinformatics, UCB, Belgium

6 14:55 Circuits mapping in animal neuroscience using a combination of optogenetics and behaviour analysis 14:55 Neuromodulation induces behavioral and cortical changes We developed a platform for investigating the effect of non-invasive brain stimulation performed during cognitive rehabilitation through high-density electroencephalography (hdeeg) recordings. hdeeg are processed with novel computational techniques providing accurate source localization; Brain activity is evaluated during working memory tasks, before and after non-invasive brain stimulation; Behavioral changes induced by non-invasive brain stimulation are associated with suppression of gamma band oscillations. Marianna Semprini, Post Doc, Italian Institute of Technology, Italy 15:25 Solution Provider Presentation; 15:25 Solution Provider Presentation; 15:40 Afternoon Refreshments and Poster Presentation One-to-One Networking Meetings End of Conference